Agree with you John, but you can't extrapolate very much and don't have a justifiable basis to, with a single product. This is contributing to the lower PE. Digging deeper, there have been multiple headwinds over axiron over last 3 years, which have provided the cap on P.
Hopefully headwinds are clearing and Q4 FY15 will see a return to growth, which the weekly sales seem to indicate.
Ann: Acrux generic strategy and Axiron patent litigation update-ACR.AX, page-24
Add to My Watchlist
What is My Watchlist?
